Best Practices, LLC Home
ABOUT US RESEARCH & CONSULTING BENCHMARKING REPORTS BEST PRACTICE DATABASE RESEARCH & ADVISORY SERVICES BEST PRACTICES EXCELLENCE SERVICES
Advanced Search
Wizards and Analytics Search
Simple Search
By Industry Focus
By Subject Area
Sales and Marketing > New Product Development and Launch > Planning and Coordinating Launch > Communication Activities
Communication Activities Research

Success Factors and Failure Points in Oncology Product Launches 
The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the oncology therapeutic area... (ID PSM-267)
Companies Profiled: GlaxoSmithKline , Bristol-Myers Squibb, Roche, Lilly, more ...
Price: $8500.00   Free Excerpt Available
Success Factors and Failure Points in Metabolic Product Launches 
The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the metabolic therapeutic area... (ID PSM-266)
Companies Profiled: GlaxoSmithKline , Bristol-Myers Squibb, Roche, Lilly, more ...
Price: $8500.00   Free Excerpt Available
Success Factors and Failure Points in Cardiovascular Product Launches 
The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the cardiovascular therapeutic area... (ID PSM-264)
Companies Profiled: GlaxoSmithKline , Bristol-Myers Squibb, Roche, Lilly, more ...
Price: $8500.00   Free Excerpt Available
New Product Launch Spend: What It Takes To Win In The U.S. Market 
In today’s pharmaceutical industry–where the recent product launch landscape is marked by as many failures as successes—it is critical for launch teams to understand the right level of resources required to give each new product its best chance for gaining a market foothold... (ID PSM-262)
Companies Profiled: Abbott, ProStrakan, Sanofi-aventis, Regeneron, more ...
Price: $8000.00   Free Excerpt Available
Educating KOLs, Physicians, Patients and Payers to Support Successful Product Launches 
The bio-pharmaceutical marketplace continues to evolve as new medicines and technologies create valuable market opportunities... (ID PSM-248)
Companies Profiled: GlaxoSmithKline , ARIAD, Pfizer, Integrated Communications Corp., more ...
Price: $8000.00   Free Excerpt Available
Educating the Marketplace to Support Successful Diabetes Product Launches 
The bio-pharmaceutical marketplace – including the diabetes therapeutic area – continues to evolve as new medicines and technologies create valuable market opportunities... (ID PSM-246)
Companies Profiled: GlaxoSmithKline , ARIAD, Pfizer, Integrated Communications Corp., more ...
Price: $8000.00   Free Excerpt Available
Shaping the Marketplace to Support Successful Oncology Product Launches: Tactics for Educating KOLs, Physicians, Patients and Payers 
The bio-pharmaceutical marketplace – and the oncology therapeutic area in particular – continues to evolve as new medicines and technologies create valuable market opportunities... (ID PSM-243)
Companies Profiled: GlaxoSmithKline , ARIAD, Pfizer, Integrated Communications Corp., more ...
Price: $8000.00   Free Excerpt Available
Pharmaceutical New Product Commercialization: Preparing for Market Success 
Long and costly product development cycles make it essential for pharmaceutical companies to maximize limited staff and resources to the development of compounds with the greatest potential market value... (ID SM-176)
Companies Profiled: Abbott, Allergan, Alexion Pharmaceuticals, Altus Biologics, more ...
Price: $7795.00   Free Excerpt Available
Best Practices for Internal Communications Regarding Brands & Disease State 
When a promising new pharmaceutical product fails to meet expectations, poor brand communications may be a contributing cause... (ID POP-229)
Companies Profiled: Abbott Laboratories, Sanofi-aventis, Actelion, Boehringer Ingelheim, more ...
Price: $7400.00   Free Excerpt Available
Best Practices for Internal Communication Regarding Brands & Disease State 
Non-members: Click here to review a complimentary excerpt from "Best Practices for Internal Communication Regarding Brands & Disease State" STUDY OVERVIEW When a promising new pharmaceutical product fails to meet expectations, poor brand communications may be a contributing cause... (ID 5055)
Companies Profiled: Abbott Laboratories, Sanofi-aventis, Actelion, Boehringer Ingelheim, more ...
Price: $7400.00   Free Excerpt Available
Raising Disease State Awareness: Best Practices in Internal Brand Messaging for New Products 
Educating the marketplace about disease state is crucial to the success of a new pharmaceutical product— especially if the product treats a medical condition that is previously unknown, socially sensitive or stigmatized or if the product is first in its class... (ID OP-106)
Companies Profiled: Abbott, Novartis, Actelion, Novo Nordisk, more ...
Price: $7200.00   Free Excerpt Available
Educating the Market to Support Successful Product Launches in Oncology 
Click Download link on right for complimentary excerpt Aggressive market pressures challenge companies to rapidly deliver new products in the market and at the same time ensure markets are well informed about in-line product launches... (ID SM-190)
Companies Profiled: GlaxoSmithKline , ARIAD, Pfizer, Integrated Communications Corp., more ...
Price: $6800.00   Free Excerpt Available
From Breakthrough to Blockbuster: Best Practices in Communicating Clinical Trial Results 
Pharmaceutical companies spend considerable resources conducting large clinical studies to support the launch of new products or expand indications for currently marketed products... (ID SM-166)
Companies Profiled: Abbott Laboratories, Sanofi-aventis, AstraZeneca, Bristol-Myers Squibb, more ...
Price: $5362.00   Free Excerpt Available
Rituxan Case Study: Pre-Launch Communications to Change the Dominant Treatment Paradigm 
Non-members: To download a complimentary excerpt of this study, please click here STUDY OVERVIEW This case study reviews the strategy and tactics utilized by Genentech for the Rheumatoid Arthritis (RA) indicated product, Rituxan, to communicate with KOLs regarding a new mechanism of action treatment for moderate-to-severe RA... (ID 5006)
Companies Profiled: Genentech
Price: $4995.00   Free Excerpt Available
Best Practices in New Product Commercialization 
Non-members: Click here for a complimentary excerpt of Best Practices in New Product Commercialization... (ID 5001)
Companies Profiled: Abbott, Allergan, Alexion Pharmaceuticals, Altus Biologics, more ...
Price: $4995.00   Free Excerpt Available
Scientific Publications Strategy: Managing Reputation, Clinical Trial Results and Commercial Relevance 
Non-members: Click here to review a complimentary excerpt from "Scientific Publications Strategy: Managing Reputation, Clinical Trial Results and Commercial Relevance" STUDY OVERVIEW Scientific journals and government regulators have increased the scrutiny and expectations for pharmaceutical companies seeking to publish their clinical trial results... (ID 4928)
Companies Profiled: Alkermes, Astellas , Baxter, Becton Dickinson, more ...
Price: $4900.00   Free Excerpt Available
Pharmaceutical New Product Commercialization: Preparing for Market Success 
Long and costly product development cycles make it essential for pharmaceutical companies to maximize limited staff and resources to the development of compounds with the greatest potential market value... (ID PSM-227)
Companies Profiled: Abbott, Allergan, Alexion Pharmaceuticals, Altus Biologics, more ...
Price: $4595.00   Free Excerpt Available
Pharmaceutical Product Launch Evaluation Excellence: Processes & Measures to Evaluate Launch Success 
In this highly competitive and scrutinized marketplace, pharmaceutical and biotech companies have continuously examined the product launch process to cut costs and to increase performance... (ID PSM-230)
Companies Profiled: Medtronic, Sanofi-aventis, Organon, Teva Pharmaceutical Industries Ltd, more ...
Price: $4500.00   Free Excerpt Available
Effient Case Study: Stumbling When Taking On The Market Leader 
Non-members: Click here to review a complimentary excerpt from "Effient Case Study: Stumbling When Taking On The Market Leader" STUDY OVERVIEW The blood thinner Effient entered the market with expectations of becoming a blockbuster for Daiichi Sankyo and Eli Lilly... (ID 5107)
Companies Profiled: Eli Lilly, Daiichi Sankyo
Price: $4500.00   Free Excerpt Available
Januvia Case Study: Building a Successful Launch Around KOL, Physician, Patient and Payer Education 
Non-members: Click here to review a complimentary excerpt from "Januvia Case Study: Building a Successful Launch Around KOL, Physician, Patient and Payer Education" STUDY OVERVIEW Approved in 2006 as a treatment for Type II diabetes, Januvia is a first-in-class oral dipeptidyl peptidase-4 that was greeted enthusiastically at launch by prescribers, payers and patients... (ID 5106)
Companies Profiled: Merck
Price: $4500.00
Pharmaceutical Product Launch Evaluation Excellence: Processes & Measures to Evaluate Launch Success 
Non-members: Click here to download a complimentary excerpt of "Pharmaceutical Product Launch Evaluation Excellence: Processes & Measures to Evaluate Launch Success" STUDY OVERVIEW In this highly competitive and scrutinized marketplace, pharmaceutical and biotech companies have continuously examined the product launch process to cut costs and to increase performance... (ID 5011)
Companies Profiled: Medtronic, Organon, Myriad, Teva Pharmaceutical Industries Ltd, more ...
Price: $4500.00   Free Excerpt Available
 


All contents copyright 1996--2012 Best Practices, LLC (919) 403-0251
Site Map | Read our Terms and Conditions of Use, Privacy Policy and Copyright Information.